[1] Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypesdealing with the diversity of breast cancer: highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J]. Ann Oncol, 2011, 22(8): 1736-1747.
[2] Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer [J]. J Clin Oncol, 2010, 28(16): 2784-2795.
[3] Guideline Recommendations for HER2 Detection in Breast Cancer Group. Guidelines for HER2 detection in breast cancer, the 2009 version[J]. Zhonghua Bing Li Xue Za Zhi, 2009, 38(12): 836-840.
[4] Donsett M, Nielsen TO, A Hern R, et al. Assessment of Ki67 in breast cancer:recommendations from the International Ki67 in Breast Cancer working group[J]. Natl Cancer Inst, 2011, 103(22): 1656-1664.
[5] Sorlie T, Peron CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications[J]. Proc Natl Acad Sci USA, 2001, 98(19): 10869-10874.
[6] Peron CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours[J]. Nature, 2000, 406(6797): 747-752.
[7] Zhao J, Liu H, Wang M, et al. Characteristics and prognosis for molecular breast cancer subtypes in Chinese women[J]. J Surg Oncol, 2009, 100(2): 89-94.
[8] 胡慧, 刘倩, 徐玲, 等. 乳腺癌临床病例分类与临床病理特征研究[J]. 中华外科杂志, 2014, 52(2):113-116.
[9] Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifentreated, nodenegative breast cancer[J]. N Engl J Med, 2004, 351(27): 2817-2826.
[10] BuenodeMesquita JM, van Harten WH, Retel VP, et al. Use of 70gene signature to predict prognosis of patients with nodenegative breast cancer:a prospective communitybased feasibility study (RASTER)[J]. Lancet Oncol, 2007, 8(12): 1079-1087.
[11] Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013[J]. Ann Oncol, 2013, 24(9): 2206-2223. |